Back to search

Netherlands· NL-b005bf567bfb

Nexviadyme100 mg poeder voor concentraat voor oplossing voor infusie

A avalglucosidase alfa product containing avalglucosidase alfa, registered in Netherlands by Genzyme Europe B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC A16AB22

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedNexviadyme100 mg poeder voor concentr…ATCA16AB22REGISTER NO.NL-b005bf567bfbPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Avalglucosidase alfa is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB22 (avalglucosidase alfa), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Avalglucosidase alfa · ATC A16AB22

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of avalglucosidase alfa costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Avalglucosidase alfa · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1265.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
AVALGLUCOSIDASE ALFA
Manufacturer
Genzyme Europe B.V.
Country
Netherlands (NL)
ATC code
A16AB22
ATC class
Avalglucosidase alfa
Defined daily dose
0.1 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/21/1579

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9ce7d245-7243-48df-8cc6-e0e11b387b03
GET /v1/drugs/9ce7d245-7243-48df-8cc6-e0e11b387b03?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Avalglucosidase alfa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127353",
  "excipients": [
    "GLYCINE (E 640)",
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "MANNITOL (D-) (E 421)",
    "POLYSORBAAT 80 (E 433)",
    "STIKSTOF (HEAD SPACE) (E 941)"
  ],
  "substances": [
    "AVALGLUCOSIDASE ALFA"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/06/24",
  "procedure_number": "EMEA/H/C/005501",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/21/1579",
  "additional_monitoring": "Y"
}

See everything about avalglucosidase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.